JPRN-UMIN000000522已完成3 期
A randomized phase III trial of AP(Doxorubicin+Cisplatin) versus DP(Docetaxel+Cisplatin), TC(Paclitaxel+Carboplatin) as adjuvant chemotherrapy in patients with high risk group of endometrial carcinoma - A randomized phase III trial of AP versus DP, TC regimens for high risk group of endometrial carcinoma
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 788
研究概览
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •1)Patients with sarcomatous element 2)Active infections 3)Serious complications (heart disease, uncontrolled diabetes mellitus, malignant hypertension and tendency to bleeding) 4)Active concomitant malignancy 5)Interstitial pneumonitis and plumonary fibrosis 6)Massive pleural effusion or ascites 7)Neuropathy grade 2 or more (NCI-CTC) 8)Edema grade 2 or more (NCI-CTC) 9)prior chemotherapy including doxorubicin 10)Hypersensitivity to Polysorbate 80 or Cremophor EL 11)Patients judged inappropriate for this study by the physicians
研究者
相似试验
进行中（未招募）
3 期
Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast CancerBreast AdenocarcinomaEstrogen Receptor NegativeHER2/Neu NegativeProgesterone Receptor NegativeStage IB Breast CancerStage IIA Breast CancerStage IIB Breast CancerStage IIIA Breast CancerStage IIIC Breast CancerTriple-Negative Breast CarcinomaNCT02488967NRG Oncology782
已完成
3 期
A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast CancerBreast CancerNCT00789581SCRI Development Innovations, LLC614
终止
3 期
Compare the Efficacy and the Safety of Taxotere and Nanoxel M as Neoadjuvant Chemotherapy in Breast CancerBreast CancerNCT05207514Samyang Biopharmaceuticals Corporation26
已完成
3 期
Doxorubicin Hydrochloride, Cisplatin, and Paclitaxel or Carboplatin and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrial CancerRecurrent Uterine Corpus CarcinomaStage IIIA Uterine Corpus Cancer AJCC v7Stage IIIB Uterine Corpus Cancer AJCC v7Stage IIIC Uterine Corpus Cancer AJCC v7Stage IVA Uterine Corpus Cancer AJCC v7Stage IVB Uterine Corpus Cancer AJCC v7NCT00063999GOG Foundation1,381
已完成
3 期
Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast CancerBreast AdenocarcinomaHER2 Positive Breast CarcinomaStage IA Breast Cancer AJCC v7Stage IB Breast Cancer AJCC v7Stage IIA Breast Cancer AJCC v6 and v7Stage IIB Breast Cancer AJCC v6 and v7Stage IIIA Breast Cancer AJCC v7NCT00005970National Cancer Institute (NCI)3,436